Text and Data Mining valid from 2019-01-21
Received: 20 September 2018
Accepted: 21 December 2018
First Online: 21 January 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: PB has received travel expenses, research funding, and speaker honoraria from Actelion Pharmaceuticals Ltd. TdK has received research funding from Actelion Pharmaceuticals Ltd. TK has received research funding, travel expenses, presentation honoraria and consulting fees from Actelion Pharmaceuticals Ltd. YN has received speech honoraria from Actelion Pharmaceuticals Ltd. and Orphan Europe, as well as travel funding from Actelion Pharmaceuticals Ltd., Shire, and Genzyme. MCP has received research grants from the Peggy Furth Fund, the National Institutes of Health [NS 65768–01], the National MS Society, Orphazyme and Actelion Pharmaceuticals Ltd., and honoraria and consulting fees from Actelion Pharmaceuticals Ltd., Alexion, Amicus, Novartis, Orphazyme, Shire HGT, Stem Cells Inc., Vtesse; stock in IntraBio; stipend and royalties from Sage Publications (Journal of Child Neurology and Child Neurology Open) and royalties from Wolters-Kluwer (Up-To-Date). MJS has received a research grant, travel expenses and speaker honoraria from Actelion Pharmaceuticals Ltd., and is a co-founder and shareholder of Genomic Consulting. MS has received travel expenses, presentation honoraria and consulting fees from Actelion Pharmaceuticals Ltd. CJH, Director of FYMCA Medical Ltd., has received consultancy fees and travel expenses from Alexion, Amicus, Biomarin, Chiesi, Inventiva, Sanofi Genzyme, and Shire, and conducted paid research on behalf of Amicus, Biomarin, Sanofi Genzyme, and Shire.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.